Skip to main content
Lincoln Pharmaceuticals ltd. logo

Lincoln Pharmaceuticals ltd. — Investor Relations & Filings

Ticker · LINCOLN ISIN · INE405C01035 LEI · 3358004B6OBJNW8RTT10 BSE.NS Manufacturing
Open in API
Filings indexed 453 across all filing types
Latest filing 2021-06-18 Regulatory Filings
Country IN India
Listing BSE.NS LINCOLN

About Lincoln Pharmaceuticals ltd.

https://www.lincolnpharma.com/

Lincoln Pharmaceuticals Ltd. focuses on the development, manufacturing, and marketing of a diverse range of therapeutic formulations. The organization operates advanced manufacturing facilities certified by international standards, including WHO-GMP. Its portfolio spans multiple areas such as anti-infectives, cardiovascular, gastrointestinal, respiratory, and pain management. The company is recognized for its research and development initiatives, particularly in Novel Drug Delivery Systems (NDDS). Key offerings include specialized treatments for tinnitus and a wide array of formulations in dosage forms like tablets, capsules, liquid orals, and injectables. It maintains a significant global footprint, supplying products to numerous international markets across Africa, Southeast Asia, and Latin America, supported by a robust distribution network for its extensive healthcare catalog.

Recent filings

Filing Released Lang Actions
Related Party Transactions
Regulatory Filings
2021-06-18 English
Copy of Newspaper Publication
Regulatory Filings
2021-05-26 English
Updates
Regulatory Filings
2021-05-25 English
Dividend Updates
Regulatory Filings Classification · 95% confidence The document is very short (616 characters) and appears to be a letter addressed to stock exchanges (NSE and BSE) regarding a listing or compliance matter. There is no substantive financial data, no mention of financial results, reports, or detailed disclosures. The content is consistent with a regulatory or compliance communication rather than a full report or announcement of financial results. Given the brevity and nature, it fits best as a Regulatory Filing (RNS), which is a fallback category for miscellaneous filings that do not fit other specific categories.
2021-05-25 English
Dividend
Regulatory Filings
2021-05-25 English
Financial Result Updates
Annual Report Classification · 95% confidence The document is a detailed announcement of the audited financial results for the quarter and year ended March 31, 2021, including standalone and consolidated financial statements, auditor's reports with unmodified opinion, dividend recommendation, and financial highlights. It references Regulation 33 of the SEBI Listing Regulations, indicating compliance with Indian stock exchange disclosure requirements. The document includes comprehensive financial data such as income, expenses, profit, assets, liabilities, and equity, along with notes explaining the accounting standards and audit committee review. The length is substantial (15,000 characters), and it contains actual financial statements and analysis, not just an announcement or summary. Therefore, this is a full Annual Report type filing, specifically the official yearly report covering company activity and full financial performance for the fiscal year ended March 31, 2021. FY 2021
2021-05-25 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.